Attached files

file filename
8-K - FORM 8-K - Simulations Plus, Inc.simulations_8k-071113.htm
EX-99.2 - POWER POINT PRESENTATION - Simulations Plus, Inc.simulations_8k-ex9902.htm

Exhibit 99.1

 

 

Simulations Plus

Integrating Science and Software

 

For Further Information:

Simulations Plus, Inc.

42505 10th Street West

Lancaster, CA 93534-7059

 

CONTACT:

Simulations Plus Investor Relations Hayden IR
Ms. Renée Bouché Mr. Cameron Donahue
661-723-7723 651-653-1854
renee@simulations-plus.com cameron@haydenir.com

 

For Immediate Release:

July 11, 2013

 

Simulations Plus Reports Third Quarter and First Nine Months

FY2013 Financial Results

 

Third quarter net sales increase 11.7%; net income up 14.3%

 

LANCASTER, CA, July 11, 2013 – Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, reported financial results for its third quarter of fiscal year 2013, the period ended May 31, 2013 (3QFY13).

 

3QFY13 highlights compared with 3QFY12:

·Net sales increased 11.7% to new third quarter record of $3.095 million from $2.772 million
·This was the Company’s 23rd consecutive profitable quarter, and the 45th of the last 47 quarters
·Gross profit increased 13.2% to $2.643 million from $2.334 million
·SG&A increased 1.4% to $0.904 million from $0.891 million
oAs a percent of revenues, SG&A decreased to 29.2% from 32.2%
·R&D expense decreased 9.5% to $206,000 from $228,000
·Income before taxes from continuing operations increased 19.7% to $1.546 million from $1.292 million
·Provision for income taxes increased 30.8% to $0.553 million from $0.423 million
·Net income from continuing operations increased 14.3% to $0.993 million from $0.869 million
·Diluted earnings per share increased 14.3% to $0.061 from $0.053 in 3QFY12
·Cash at the end of the third fiscal quarter was $10.005 million after our recent dividend distributions
oApproximately $796,000 was distributed in November 2012
oApproximately $2,243,000 was distributed in December 2012
oApproximately $480,000 was distributed in May 2013
oCash as of July 7 was $10.322 million
·Shareholders’ equity at the end of the quarter was $14.461 million
oThis is a decrease of $0.944 million from $15.143 million at the end of 3QFY12
oThis decrease was after dividend distributions of approximately $5.4 million during calendar 2012 and $0.48 million in May 2013

 

 
 

For the first nine months of fiscal year 2013 (9moFY13) compared to the first nine months of fiscal year 2012 (9moFY12):

·Net sales increased 8.9% to a new nine-month record $8.503 million from $7.809 million
·Gross profit increased 8.2% to $7.165 million from $6.622 million
·SG&A increased 5.6% to $2.690 million from $2.548 million
oAs a percent of revenues, SG&A decreased to 31.6% from 32.6%
·R&D expense decreased 14.8% to $634,000 from $745,000
oCompletion of the Company's malaria NCE project reduced R&D expenditures in the current year
·Income before taxes increased 11.0% to $4.014 million from $3.615 million
·Provision for income taxes increased 19.1% to $1.372 million from $1.152 million
·Net income from continuing operations increased 7.3% to $2.642 million from $2.463 million
·For 9moFY13, earnings per share from continuing operations increased 5.7% to $0.162 per share from $0.153 per share
·Including the $0.216 million net proceeds from the sale of the former Words+ subsidiary last year, net income for 9moFY12 was $2.679 million
·Including the $0.216 million net proceeds from the sale of the former Words+ subsidiary last year, total diluted earnings per share for 9moFY12 was $0.167

 

Ms. Momoko Beran, chief financial officer of Simulations Plus, said: “For the third quarter of fiscal year 2013, Simulations Plus delivered revenue growth of nearly 12% and continued high gross margins, exceeding 84%. As a result, net income increased 14.3% despite a substantial increase in income tax rates and a decrease on other income of over $100,000. After distributing cash dividends of approximately $5.4 million to our shareholders during calendar 2012 and another $480,000 in May 2013, our cash position remains strong, and we continue to have no debt. Cash as of July 7 was $10.322 million.”

 

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “The third quarter continues our trend of setting new quarterly records each fiscal quarter. During 3QFY13, we added 16 new customers, had 94% renewals, and increased our collaboration funding by $91,250, while consulting revenues increased $73,500. We attended a total of 19 scientific meetings and conferences, conducted 8 training workshops, including training over 20 scientists at the U.S. FDA and 15 at the U.S. EPA.”

 

Investor Conference Call

 

The Company has announced an investor conference call that will be webcast live at 1:15 PDT/4:15 PM EDT Thursday, July 11, 2013, which may be accessed by first registering here. Upon registering, you will receive a confirmation e-mail with a unique link and instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (702) 489-0004, and enter access code 571-860-333.

 

About Simulations Plus, Inc.

 

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. We also provide a productivity tool called Abbreviate! for PCs. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.

 

Follow Us on Twitter

 

2
 

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

 

-- Tables Follow –

 

 

3
 

SIMULATIONS PLUS, INC.

CONDENSED STATEMENTS OF OPERATIONS

For the three and nine months ended May 31,

(Unaudited)

 

   Three months ended   Nine months ended 
   2013   2012   2013   2012 
                 
Net sales  $3,094,779   $2,771,500   $8,502,994   $7,808,682 
Cost of sales   451,935    437,734    1,337,583    1,186,670 
Gross profit   2,642,844    2,333,766    7,165,411    6,622,012 
Operating expenses                    
Selling, general, and administrative   903,589    891,131    2,689,632    2,547,569 
Research and development   206,424    228,163    634,281    744,679 
Total operating expenses   1,110,013    1,119,294    3,323,913    3,292,248 
                     
Income from operations   1,532,831    1,214,472    3,841,498    3,329,764 
                     
Other income (expense)                    
Interest income   9,203    22,572    40,005    69,528 
Interest expense               (3)
Miscellaneous income   4,694    25,011    35,488    47,667 
Gain (loss) currency exchange   (980)   29,802    96,662    168,690 
Gain (loss) from sale of assets               (433)
Total other income (expense)   12,917    77,385    172,155    285,449 
Income from continuing operations before provision for income taxes   1,545,748    1,291,857    4,013,653    3,615,213 
Provision for income taxes   (552,518)   (422,524)   (1,371,862)   (1,152,204)
Income from continuing operations   993,230    869,333    2,641,791    2,463,009 
                     
Discontinued operations:                    
Gain (loss) from discontinued operations, net of tax               (249,898)
Gain on sale of Words+, net of tax               465,820 
Results of discontinued operations   993,230    869,333    2,641,791    2,678,931 
                     
Net Income  $993,230   $869,333   $2,641,791   $2,678,931 
                     
Basic earnings per share:                    
Continuing operations  $0.06   $0.05   $0.17   $0.16 
Discontinued operations               0.01 
Net basic earning per share  $0.06   $0.05   $0.17   $0.17 
Diluted earnings per share                    
Continuing operations  $0.06   $0.05   $0.16   $0.15 
Discontinued operations               0.01 
Net basic earning per share  $0.06   $0.05   $0.16   $0.16 
                     
Weighted-average common shares outstanding                    
Basic   16,024,467    15,918,905    15,984,819    15,710,014 
Diluted   16,335,608    16,340,765    16,307,618    16,070,478 

 

4
 

SIMULATIONS PLUS, INC. CONDENSED BALANCE SHEETS

at May 31, 2013 (Unaudited) and August 31, 2012 (Audited)

 

ASSETS 
   May 31,   August 31, 
   2013   2012 
Current assets          
Cash and cash equivalents  $10,005,490   $12,701,075 
Income tax refund receivable       153,896 
Accounts receivable, net of allowance for doubtful accounts of $0   2,941,428    1,451,864 
Contracts receivable   141,167    18,893 
Prepaid expenses and other current assets   137,572    150,856 
Deferred income taxes   216,331    193,712 
Total current assets   13,441,988    14,670,296 
Long-term assets          
Capitalized computer software development costs, net of accumulated amortization of $5,616,797 and $5,084,691   2,781,327    2,479,468 
Property and equipment, net   95,258    107,410 
Intellectual property, net of accumulated amortization of $9,375 and $3,750   65,625    71,250 
Other assets   18,445    18,445 
Total assets  $16,402,643   $17,346,869 
           
           
LIABILITIES AND SHAREHOLDERS' EQUITY 
Current liabilities          
Accounts payable  $221,715   $177,509 
Accrued payroll and other expenses   337,885    312,912 
Accrued bonuses to officer   45,000    60,000 
Accrued income taxes   258,692    733,233 
Deferred revenue   167,106    131,782 
Total current liabilities   1,030,398    1,415,436 
           
Long-term liabilities          
Deferred income taxes   910,878    788,857 
Total liabilities   1,941,276    2,204,293 
           
Commitments and contingencies          
           
Shareholders' equity          
Preferred stock, $0.001 par value 10,000,000 shares authorized no shares issued and outstanding        
Common stock, $0.001 par value 50,000,000 shares authorized 16,030,894 and 15,923,019 shares issued and outstanding   4,502    4,399 
Additional paid-in capital   4,825,548    4,628,366 
Retained earnings   9,631,317    10,509,811 
           
Total shareholders' equity   14,461,367    15,142,576 
           
Total liabilities and shareholders' equity  $16,402,643   $17,346,869 

 

 

5